Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Everolimus|BIOLOGICAL: Trastuzumab
Sponsor: Emory University
Collaborators: Genentech, Inc.|Novartis Pharmaceuticals